Abstract Library

#2296 First Patient Survey about Tumor - Associated Fatigue in NEN

Introduction: Tumor-associated fatigue (TrF) is a debilitating condition occurring during the course of the tumor disease, and even ongoing after all tumor specific therapies are completed. The syndrome consists of chronic fatigue, sleep disturbances, severe pain, brain-fog and is underestimated by both, patients and doctors. Diagnosis is made according to the criteria by Cella (Cella 2001), although it is felt not to be sufficient.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Germany P

Authors: Banz S, Mellar K, Letsch A, Scheibenbogen C, Pavel M,

Keywords: Tumor related fatigue, online survey, support group, Quality of Life, ability of work,

#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens

Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dal Buono A

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: well-differentiated, platinum, streptozotocin,

#2113 How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms

Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Fahlenkamp U, Prasad V, Pavel M, Geisel D,

Keywords: magnetic resonance, hepatocyte specific, liver specific, gadoxetate, gadoxetic acid, neuroendocrine, staging, shuttle, large bore, whole abdomen, pelvis, extrahepatic evaluation,

#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study

Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,

Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,

#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,

Keywords: PDR001, immunotherapy, NET,